Thomas Habermann

Department of Medicine, Division of Hematology, Mayo Clinic, United States of America

Thomas M. Habermann, M.D.

Academic positions:
- Professor of Medicine

All industry positions (in last five years):

Research interests:
Malignant Lymphomas, Hodgkins disease, hairy cell leukemia, post-transplant lymphoproliferative disorders

Any other information:

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Hematology > Lymphomas & Myelomas (since 23 November 2006)

Links

http://www.mayoclinic.org/hematology-rst/index.html

All recent recommendations

• 3.0
  Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
  Recommended by Thomas Habermann
  
• 3.0
  Borrelia infection and risk of non-Hodgkin lymphoma.
  Recommended by Thomas Habermann
  
• 4.9
  Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
  Recommended by Nicolas Mounier, Thomas Habermann, Stefano Pileri
  
• 3.0
  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.
  Recommended by Thomas Habermann
  
• 3.0
  The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
  Recommended by Thomas Habermann
  
• 3.0
  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
  Recommended by Thomas Habermann
  
• 4.8
  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
  Recommended by Thomas Habermann, Sebastian Giebel